After therapy, there was a considerable rise in immune cytokines TNF-α, IL-6, and IFN-γ in peripheral blood serum, as well as a robust infiltration of CD8+ T cells at primary and distant tumor sites, resulting in systemic therapeutic antitumor effects. Here, CD8A is linked to neoplasm.